Clinical Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 680s, January 15, 2007. doi: 10.1158/1078-0432.CCR-06-1865
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaelin, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaelin, W. G., Jr.

Innovations and Challenges in Renal Cancer

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

William G. Kaelin, Jr.

Author's Affiliation: Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: William G. Kaelin, Jr., Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115. Phone: 617-632-3975; Fax: 617-632-4760; E-mail: William_kaelin{at}dfci.harvard.edu.


   Abstract
Top
 Abstract
Open Discussion
 References
 
Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the {alpha}-subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitylation, and hence, proteasomal degradation, when oxygen is available. pVHL-defective clear cell renal carcinomas overproduce a variety of mRNAs that are under the control of HIF, including the mRNAs that encode vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor {alpha}. In preclinical models, down-regulation of HIF-{alpha}, especially HIF-2{alpha}, is both necessary and sufficient for renal tumor suppression by pVHL. These observations are probably relevant to the demonstrated clinical activity of vascular endothelial growth factor antagonists in clear cell renal carcinoma and form a foundation for the testing of additional agents that inhibit HIF, or HIF-responsive gene products, in this disease.

Inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which is located on chromosome 3p25, plays an important role in hereditary (VHL disease) and sporadic clear cell renal carcinoma, which is the most common form of kidney cancer (1). The VHL gene product, pVHL, has multiple functions, but the one that has been most extensively studied relates to the regulation of the transcription factor called hypoxia-inducible factor (HIF). HIF is a heterodimer that consists of an unstable {alpha}-subunit (such as HIF-1{alpha}) and a stable ß-subunit (such as HIF-1ß, also called ARNT1). There are three HIF-{alpha} genes in the human genome, although only HIF1-{alpha} and HIF2-{alpha} have been well documented to activate transcription in mammalian cells under physiologic conditions. In fact, some HIF3-{alpha} splice variants probably act as dominant-negative inhibitors of HIF activity (2–4). In the presence of oxygen, HIF-{alpha} ("HIF-{alpha}" will be used in the remainder of this review when referring to the three HIF{alpha} family members generically) subunits become hydroxylated on one (or both) of two prolyl residues (5–9). Hydroxylation of either site, which is carried out by members of the EglN family (also called PHDs or HPHs; refs. 10–12), generates a binding site for pVHL. pVHL is the substrate recognition component of a multisubunit ubiquitin ligase complex that also contains elongin B, elongin C, Cul2, and Rbx1 (also called Roc1). pVHL directs the polyubiquitylation of HIF-{alpha}, which in turn, earmarks HIF-{alpha} for proteasomal degradation (13–16). In cells that lack functional pVHL or that are exposed to low oxygen (hypoxia), HIF-{alpha} subunits accumulate and bind to a HIF-ß partner protein (17). This HIF heterodimer binds to specific DNA sequences and transcriptionally activates genes involved in acute or chronic adaptation to hypoxia, such as vascular endothelial growth factor (VEGF) and erythropoietin. Overproduction of such hypoxia-inducible mRNAs is a hallmark of pVHL-defective tumors (18).

Humans carrying one wild-type VHL allele and one mutated VHL allele in their germ line develop VHL disease, which is associated with an increased risk of a variety of tumors, including central nervous system (especially cerebellum and spinal cord) hemangioblastomas and pheochromocytomas, in addition to kidney cancer (19). The risk of these different tumors is influenced by the nature of the VHL mutation. In other words, there are strong genotype-phenotype correlations in VHL disease. VHL families have been subdivided into those with a low risk of pheochromocytoma (type 1 VHL disease) and those with a high risk of pheochromocytoma (type 2 VHL disease). Type 2 families almost invariably have missense VHL mutations, whereas many different types of mutations, including nonsense and deletion VHL mutations, have been linked to type 1 VHL disease. Type 2 VHL disease has been subdivided into type 2A (low risk of renal carcinoma), type 2B (high risk of renal carcinoma), and type 2C (familial pheochromocytoma without hemangioblastoma and clear cell renal carcinoma). VHL alleles linked to type 1, type 2A, and type 2B VHL disease encode proteins that are at least partially defective with respect to HIF-{alpha} regulation, whereas the products of type 2C VHL alleles are grossly normal with respect to HIF (20, 21). The products of type 2C VHL alleles are defective, however, with respect to another pVHL function, i.e., down-regulation of atypical protein kinase C activity (22–25). Increased atypical protein kinase C activity, and consequent up-regulation of JunB, seems to promote the survival of pheochromocytoma cells when growth factors such as nerve growth factor become limiting (22).

In VHL disease, stochastic loss of the remaining wild-type VHL allele in the kidney causes the development of renal cysts (26). The precise cell of origin in these lesions is debated but might be a distal renal tubular epithelial cell (26). Regardless of the cell of origin, it is presumed that mutations at other loci are required to convert these cysts to renal cell carcinomas. A total of 40% to 80% of sporadic clear cell renal carcinomas are linked to biallelic VHL inactivation, and in some VHL+/+ clear cell renal carcinomas, little or no VHL mRNA is produced as a result of promoter hypermethylation (1).

Restoration of wild-type pVHL function in VHL–/– renal carcinoma cells suppresses their ability to form tumors in nude mice (27, 28). Although pVHL does not grossly alter cell proliferation under standard cell culture conditions, it induces a number of phenotypes in vitro that are likely to correlate with tumor suppression in vivo. These include enhanced cell cycle exit under low serum conditions and enhanced cell differentiation in monolayer and spheroid growth assays (29–34). In particular, restoration of pVHL function in VHL–/– renal carcinoma cells is able to induce a mesenchymal to epithelial transition.

VHL+/– mice develop liver hemangiomas but do not develop the lesions typical of human VHL disease (35). Similar hepatic lesions develop after Cre recombinase–mediated inactivation of VHL in the livers of VHL flox/flox mice (35, 36). These lesions are characterized by elevated levels of HIF-{alpha} and HIF-responsive gene products such as VEGF. Importantly, these lesions do not develop in mice that lack HIF-1ß, also called aryl hydrocarbon receptor nuclear translocator (ARNT1), suggesting that HIF-{alpha} function is necessary for these pathologic changes (37). In a complementary set of experiments, we found that hepatic expression of a stabilized version of HIF-2{alpha} in genetically engineered mice is sufficient to induce many of the pathologic changes attributed to pVHL loss (38).

VHL–/– embryos are not viable, and conditional, systemic, inactivation of VHL in adult mice is lethal (36, 39). Haase and coworkers recently reported that inactivation of VHL in the mouse kidney, using Cre recombinase under the control of the phosphoenolpyruvate carboxykinase promoter, caused the development of polycythemia and renal cysts (40). These results, however, are complicated by the fact that the Cre transgene was also expressed in the liver. Renal pathology was not observed in a mouse in which VHL was inactivated in a systemic mosaic pattern (36).

HIF-{alpha}, especially HIF-2{alpha}, seems to play a special role with respect to VHL–/– renal carcinogenesis. First, VHL–/– renal carcinomas seem to produce both HIF-1{alpha} and HIF-2{alpha} or HIF-2{alpha} alone (17). Second, the appearance of HIF-2{alpha} in VHL–/– preneoplastic lesions arising from VHL+/– kidneys is associated with increased dysplasia (26). Third, the elimination of HIF-2{alpha}, like the restoration of pVHL function, is sufficient to suppress VHL–/– tumor growth in vivo (41, 42). Fourth, tumor suppression by pVHL can be overridden by HIF-2{alpha} but not by HIF-1{alpha} (41, 43–45). Finally, type 2B pVHL mutants, which are associated with a high risk of renal carcinoma, are more defective with respect to HIF-{alpha} regulation than type 2A mutants (46).1 Collectively, these results implicate dysregulation of HIF target genes as playing a causal role in the pathogenesis of pVHL-defective clear cell renal carcinomas.

Why pVHL and HIF, both of which are ubiquitously expressed, play such an important role in human clear cell renal carcinoma is not clear, but several observations might be relevant. First, renal epithelia seem to be particularly sensitive to the mitogenic effects of the HIF-responsive growth factor transforming growth factor {alpha} among various epithelia tested (47). Second, hypoxia and HIF cause the up-regulation of cyclin D1 (Fig. 1 ), which with its catalytic partners, cdk4 and cdk6, stimulates cell proliferation by directing the phosphorylation of the pRB tumor suppressor protein, in renal epithelia but not in other cells types (45, 48–50). Finally, portions of the kidney in mammals (especially the medulla) are hypoxic at rest (51). Epigenetic differences between the kidney and other organs that allow renal cells to proliferate in a hypoxic environment might also make them more susceptible to the oncogenic effects of pVHL loss/HIF activation.


Figure 1
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Potential cancer drug targets linked to pVHL and HIF. pVHL inhibits the heterodimeric transcription factor HIF by targeting it for proteasomal degradation. HIF protein levels are also sensitive to changes in histone deacetylase (HDAC), heat shock protein 90 (HSP90), and mTOR activities. HIF transcriptionally activates >100 genes, including many suspected or known to play roles in tumorigenesis (solid arrows). Sorafinib and sunitinib inhibit signaling by the VEGF receptor KDR and platelet-derived growth factor receptor (PDGFR). See text for details.

 
Kidney cancers are notoriously resistant to standard chemotherapy and radiotherapy. It has been suggested that this resistance might be due, at least in part, to increased levels of the transcription factor nuclear factor {kappa}B (52, 53). Loss of VHL leads to increased nuclear factor {kappa}B activity and resistance to apoptosis (54, 55). One study suggested that increased levels of HIF-{alpha} were necessary and sufficient for the activation of nuclear factor {kappa}B, although this work needs to be independently corroborated (56). We have obtained evidence of a HIF-independent link between pVHL and nuclear factor {kappa}B.2

These considerations suggest that drugs which target HIF, or HIF-responsive gene products, should be effective in the treatment of renal carcinomas. Unfortunately, DNA-binding transcription factors, with the exception of the steroid hormone receptors, have proven difficult to inhibit with drug-like small organic molecules. However, a number of drugs have been identified that indirectly down-regulate HIF-{alpha}, including drugs that inhibit mTOR (57–61), HSP90 (62, 63), and histone deacetylases (64). These drugs clearly warrant investigation in pVHL-defective renal carcinomas. In one phase 3 trial, patients with poor prognosis renal carcinoma treated with the mTOR inhibitor, CCI-779, fared better than patients treated with IFN with respect to time to progression and overall survival (65).

HIF-responsive gene products that are suspected or known to play a role in renal tumorigenesis include VEGF, platelet-derived growth factor B, c-Met (66–68), transforming growth factor {alpha} (47, 69, 70), transforming growth factor ß (71), CXCR4 (and its ligand SDF1; refs. 72, 73), and certain matrix metalloproteinase (refs. 74, 75; Fig. 1). It is worth noting that overproduction of VEGF probably occurs very early during the development of VHL–/– renal cell carcinomas and therefore reduces the selection pressure to activate "collateral" angiogenic pathways (26, 76, 77). This might explain why renal cell carcinomas are the only solid tumors where agents that inhibit VEGF, or its receptor KDR, have significant activity as single agents. Indeed, two such agents (sorafenib and sunitinib) were recently approved by the Food and Drug Administration for this indication. These drugs both inhibit KDR in addition to some other receptor tyrosine kinases, including the platelet-derived growth factor receptor. This might be fortuitous because dual inhibition of VEGF and platelet-derived growth factor signaling is more effective at inducing the regression of established tumor blood vessels than is VEGF blockade alone in preclinical models (78, 79). It will be important to determine whether the VHL genotype influences the responsiveness to VEGF inhibitors, as well as the molecular basis for acquired or de novo resistance. VEGF inhibitors can now serve as a platform for building rational combinations that target additional HIF-responsive growth factors and/or incorporate drugs that down-regulate HIF itself.


   Open Discussion
Top
 Abstract
 Open Discussion
References
 
Dr. Atkins: Is something other than the hypoxia-inducible factor driving the von Hippel-Lindau wild-type clear cell renal cancer?

Dr. Kaelin: In most VHL wild-type renal carcinoma cell lines, it looks like HIF is regulated appropriately, meaning at least it is responsive to hypoxia. I don't know what is driving VHL wild-type clear cell renal cancer.

Dr. Figlin: You said that with VHL loss, angiogenesis through the vascular endothelial growth factor pathway dominates. If that were true, wouldn't we have seen more robust clinical activity from VEGF pathway inhibitors in the form of complete responses?

Dr. Kaelin: I am a believer of the preclinical work performed by Ellie Keshet in Israel and Doug Hannahan at the University of California, San Francisco, which strongly suggests that newly sprouting blood vessels, before they are properly invested with pericytes and surrounding stroma, are exquisitely sensitive to, and will regress upon, VEGF withdrawal. However, once you have a mature vessel that is properly enveloped with pericytes and stroma, VEGF inhibitors no longer cause regression; they cause stasis.

Dr. Kwon: Is there any thinking that HIF may be a relatively late player in tumor progression?

Dr. Kaelin: I cannot prove that VHL loss is an early event versus a late event in sporadic clear cell carcinoma. At least in VHL disease, it appears that VHL loss is an early event and sufficient to cause renal cysts. Therefore, your question really is why would VHL loss give rise to renal cysts? VHL loss leads to up-regulation of cyclin D1 and gives rise to transforming growth factor {alpha}. We know that one of the features of renal cystic diseases is increased proliferation of renal epithelial cells, which might be due to cyclin D1 or transforming growth factor-{alpha}. Another feature is alterations in epithelial stromal interactions, and there is a role for VHL in the regulation of the extracellular matrix. Again, it is partly related to HIF. Several groups have shown that when you inactivate VHL in a renal epithelial cell, the cell undergoes an epithelial to mesenchymal transition. You can reverse that by putting VHL back in. There are a lot of effects of VHL loss that might translate into renal cyst formation. Although you might have expected HIF deregulation to be a late event, at least in renal cancer, it can be an early event.

Dr. Kwon: Is there a possibility that the inadequacy of angiogenesis inhibition may be in part related to exacerbation of hypoxia of the tumor and subsequent induction of more HIF?

Dr. Kaelin: As the tumor expands and hypoxia occurs in the surrounding normal tissues that are being compressed, the normal host becomes a source of angiogenic growth factors. Therefore, as you treat these tumors with an angiogenesis inhibitor, it is likely that you exacerbate hypoxia.

Dr. Kwon: What are the driving molecules that push the inception of the tumor?

Dr. Kaelin: I have satisfied myself as best I can that HIF is the driver.

Dr. Sosman: Some recent data from Neal Rosen and his colleagues has shown that if you block mTOR, you induce a feedback that enhances AKT activity. Is that pathway important in renal cancer outside mTOR-regulating HIF?

Dr. Kaelin: mTOR inhibitors down-regulate HIF, at least in cell culture. I do not know whether indirect effects on AKT signaling might offset any benefits of down-regulating HIF.

Dr. Sukhatme: At least two reports have shown that if you introduce a nondegradable HIF1 into a tumorigenic cell line, you get a decreased growth rate, but if you introduce a dominant-negative you get even faster growth. Are you concerned about HIF inhibitors in this context or is there something peculiar about that data with HIF1-{alpha} versus HIF2-{alpha}?

Dr. Kaelin: Emerging data suggest that whether HIF1 can promote or inhibit tumor growth depends on what cell type are you looking at and in what context that cell is growing.


   Footnotes
 
Presented at the Second Cambridge Conference on Innovations and Challenges in Renal Cancer, March 24-25, 2006, Cambridge, Massachusetts.

1 Lianjie Li and Kaelin W.G., unpublished data. Back

2 Haifeng Yang and Kaelin W.G., unpublished data. Back

Received 7/27/06; revised 11/ 7/06; accepted 11/10/06.


   References
Top
 Abstract
 Open Discussion
 References
 

  1. Kim WY, Kaelin WG. Role of VHL Gene mutation in human cancer. J Clin Oncol 2004;22:4991–5004.[Abstract/Free Full Text]
  2. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550–4.[CrossRef][Medline]
  3. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3{alpha} locus. J Biol Chem 2002;277:32405–8.[Abstract/Free Full Text]
  4. Maynard MA, Evans AJ, Hosomi T, Hara S, Jewett MA, Ohh M. Human HIF-3{alpha}4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J 2005;19:1396–406.[Abstract/Free Full Text]
  5. Ivan M, Kondo K, Yang H, et al. HIF{alpha} targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464–8.[Abstract/Free Full Text]
  6. Yu F, White S, Zhao Q, Lee F. HIF-1{alpha} binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 2001;98:9630–5.[Abstract/Free Full Text]
  7. Jaakkola P, Mole D, Tian Y, et al. Targeting of HIF-{alpha} to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468–72.[Abstract/Free Full Text]
  8. Masson N, Willam C, Maxwell P, Pugh C, Ratcliffe P. Independent function of two destruction domains in hypoxia-inducible factor-a chains activated by prolyl hydroylation. EMBO J 2001;20:5197–206.[CrossRef][Medline]
  9. Chan DA, Sutphin PD, Yen SE, Giaccia AJ. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1{alpha}. Mol Cell Biol 2005;25:6415–26.[Abstract/Free Full Text]
  10. Epstein A, Gleadle J, McNeill L, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43–54.[CrossRef][Medline]
  11. Bruick R, McKnight S. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337–40.[Abstract/Free Full Text]
  12. Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 2002;99:13459–64.[Abstract/Free Full Text]
  13. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1{alpha} by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19:4298–309.[CrossRef][Medline]
  14. Cockman M, Masson N, Mole D, et al. Hypoxia inducible factor-{alpha} binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733–41.[Abstract/Free Full Text]
  15. Kamura T, Sato S, Iwain K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1{alpha} ubiquitination by a reconstituted von Hippel-Lindau tumor suppressor complex. Proc Natl Acad Sci U S A 2000;97:10430–5.[Abstract/Free Full Text]
  16. Ohh M, Park CW, Ivan M, et al. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein ß domain. Nat Cell Biol 2000;2:423–7.[CrossRef][Medline]
  17. Maxwell P, Weisner M, Chang G-W, et al. The von Hippel-Lindau gene product is necessary for oxygen-dependent proteolysis of hypoxia-inducible factor {alpha} subunits. Nature 1999;399:271–5.[CrossRef][Medline]
  18. Iliopoulos O, Jiang C, Levy AP, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595–9.[Abstract/Free Full Text]
  19. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673–82.[CrossRef][Medline]
  20. Hoffman M, Ohh M, Yang H, Klco J, Ivan M, Kaelin WJ. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019–27.[Abstract/Free Full Text]
  21. Clifford S, Cockman M, Smallwood A, et al. Contrasting effects on HIF-1{alpha} regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029–38.[Abstract/Free Full Text]
  22. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005;8:155–67.[CrossRef][Medline]
  23. Okuda H, Hirai S, Takaki Y, et al. Direct interaction of the ß-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491–7.[CrossRef][Medline]
  24. Okuda H, Saitoh K, Hirai S, et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001;276:43611–7.[Abstract/Free Full Text]
  25. Pal S, Claffey K, Dvorak H, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997;272:27509–12.[Abstract/Free Full Text]
  26. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459–68.[CrossRef][Medline]
  27. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822–6.[CrossRef][Medline]
  28. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci U S A 1996;93:10589–94.[Abstract/Free Full Text]
  29. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998;95:993–8.[Abstract/Free Full Text]
  30. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel R. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998;58:4957–62.[Abstract/Free Full Text]
  31. Davidowitz E, Schoenfeld A, Burk R. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001;21:865–74.[Abstract/Free Full Text]
  32. Krishnamachary B, Zagzag D, Nagasawa H, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, ZFHX1B. Cancer Res 2006;66:2725–31.[Abstract/Free Full Text]
  33. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, et al. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res 2006;66:1553–60.[Abstract/Free Full Text]
  34. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel-Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006;66:1313–9.[Abstract/Free Full Text]
  35. Haase V, Glickman J, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 2001;98:1583–8.[Abstract/Free Full Text]
  36. Ma W, Tessarollo L, Hong SB, et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 2003;63:5320–8.[Abstract/Free Full Text]
  37. Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 2005;25:3163–72.[Abstract/Free Full Text]
  38. Kim WY, Safran M, Buckley MR, et al. Failure to prolyl hydroxylate hypoxia-inducible factor {alpha} phenocopies VHL inactivation in vivo. EMBO J 2006;25:4650–62.[CrossRef][Medline]
  39. Gnarra J, Ward J, Porter F, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 1997;94:9102–7.[Abstract/Free Full Text]
  40. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006;66:2576–83.[Abstract/Free Full Text]
  41. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2{alpha} is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.[Medline]
  42. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL–/– tumors. Mol Cancer Res 2004;2:89–95.[Abstract/Free Full Text]
  43. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237–46.[CrossRef][Medline]
  44. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-{alpha} to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247–55.[CrossRef][Medline]
  45. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675–86.[Abstract/Free Full Text]
  46. Knauth K, Bex C, Jemth P, Buchberger A. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1{alpha} interactions. Oncogene 2006;25:370–7.[Medline]
  47. de Paulsen N, Brychzy A, Fournier M-C, et al. Role of transforming growth factor-{alpha} in VHL–/– clear cell renal carcinoma cell proliferation: a possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 2001;13:1387–92.
  48. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002;62:3014–9.[Abstract/Free Full Text]
  49. Zatyka M, da Silva NF, Clifford SC, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 2002;62:3803–11.[Abstract/Free Full Text]
  50. Baba M, Hirai S, Yamada-Okabe H, et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of cyclin D1 expression through hypoxia-inducible factor. Oncogene 2003;22:2728–38.[CrossRef][Medline]
  51. Brezis M, Rosen S. Hypoxia of the renal medulla-its implications for disease. N Engl J Med 1995;332:647–55.[Free Full Text]
  52. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M. Constitutive activation of nuclear factor-{kappa}B prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001;20:3888–96.[CrossRef][Medline]
  53. Oya M, Takayanagi A, Horiguchi A, et al. Increased nuclear factor-{kappa}B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003;24:377–84.[Abstract/Free Full Text]
  54. An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-{kappa}B-dependent mechanism. Oncogene 2005;24:1563–70.[CrossRef][Medline]
  55. Qi H, Ohh M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-{kappa}B-dependent antiapoptotic pathway. Cancer Res 2003;63:7076–80.[Abstract/Free Full Text]
  56. An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor {kappa}B activity. Mol Cell Biol 2005;25:7546–56.[Abstract/Free Full Text]
  57. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1{alpha} expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004–14.[Abstract/Free Full Text]
  58. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1{alpha} expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541–5.[Abstract/Free Full Text]
  59. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003;278:29655–60.[Abstract/Free Full Text]
  60. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147–58.[CrossRef][Medline]
  61. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122–7.[CrossRef][Medline]
  62. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1{alpha}-degradative pathway. J Biol Chem 2002;277:29936–44.[Abstract/Free Full Text]
  63. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55–61.[CrossRef][Medline]
  64. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437–43.[CrossRef][Medline]
  65. Hudes G, Carducci M, Tomczak J, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-{alpha} (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). JCO 2006 ASCO Annual Meetings Proceedings Part I 2006;24:LBA4.
  66. Hara S, Nakashiro KI, Klosek SK, Ishikawa T, Shintani S, Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1{alpha} in human salivary gland cancer cells. Oral Oncol 2006;42:593–8.[CrossRef][Medline]
  67. Hayashi M, Sakata M, Takeda T, et al. Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1{alpha} is involved in trophoblast invasion under low-oxygen tension. Endocrinology 2005;146:4682–9.[Abstract/Free Full Text]
  68. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347–61.[CrossRef][Medline]
  69. Knebelmann B, Ananth S, Cohen H, Sukhatme V. Transforming growth factor {alpha} is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226–31.[Abstract/Free Full Text]
  70. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL–/– renal cancer. Cancer Res 2005;65:5221–30.[Abstract/Free Full Text]
  71. Ananth S, Knebelmann B, Gruning W, et al. Transforming growth factor ß1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999;59:2210–6.[Abstract/Free Full Text]
  72. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307–11.[CrossRef][Medline]
  73. Zagzag D, Krishnamachary B, Yee H, et al. Stromal cell-derived factor-1{alpha} and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005;65:6178–88.[Abstract/Free Full Text]
  74. Koochekpour S, Jeffers M, Wang P, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902–12.[Abstract/Free Full Text]
  75. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2{alpha} in von Hippel-Lindau renal cell carcinoma. Oncogene 2005;24:1043–52.[CrossRef][Medline]
  76. Zhuang Z, Bertheau P, Emmert-Buck M, et al. A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol 1995;146:620–5.[Abstract]
  77. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996;149:2089–94.[Abstract]
  78. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159–65.[Medline]
  79. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287–95.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Therapeutic Advances in Medical OncologyHome page
J. M.G. Larkin, E. L.S. Kipps, C. J. Powell, and C. Swanton
Review: Systemic therapy for advanced renal cell carcinoma
Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 15 - 27.
[Abstract] [PDF]

Home page
 Ann OncolHome page
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc., March 1, 2009; 20(3): 413 - 424.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Toschi, E. Lee, N. Gadir, M. Ohh, and D. A. Foster
Differential Dependence of Hypoxia-inducible Factors 1{alpha} and 2{alpha} on mTORC1 and mTORC2
J. Biol. Chem., December 12, 2008; 283(50): 34495 - 34499.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Lee and V. Vasioukhin
Cell polarity and cancer - cell and tissue polarity as a non-canonical tumor suppressor
J. Cell Sci., April 15, 2008; 121(8): 1141 - 1150.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaelin, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaelin, W. G., Jr.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online